Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
With oil prices, presidential politics, and the Olympics having dominated the news this summer and fall, people may have not heard much about the International AIDS Conference, held in Mexico City in August. Here is the headline story: The controversy and confusion about the efficacy and safety of abacavir (Ziagen) that started at the retrovirus conference last winter only heated up in Mexico City. Presentation of the ongoing analysis of ACTG 5202 -- comparing abacavir to tenofovir (Viread) in combination with either efavirenz (Sustiva) or boosted atazanavir (Reyataz) -- continued to show abacavir-containing regimens failing more often than tenofovir-containing regimens in patients who have viral loads greater than 100,000. At the same time, the comparison of abacavir to tenofovir in combination with boosted lopinavir (Kaletra) in the HEAT study showed no difference. In addition, GlaxoSmithKline, the manufacturer of abacavir, reanalyzed six other abacavir studies and found no difference in virologic control with abacavir in patients with viral loads above or below 100,000. There was also continuing dueling data about the possible increased risk of cardiovascular events in patients taking abacavir compared to other nucleosides, first reported in the D:A:D study at the retrovirus conference. This time, data from the SMART study was examined. Again, those patients who were on abacavir had more cardiovascular events compared to those on other nucleosides as a whole -- but only if they already had multiple other cardiovascular risk factors. What was not presented was data on cardiovascular events specifically for those patients on tenofovir, the drug most likely to be used in place of abacavir. These data were published in the journal AIDS in September. Meanwhile, GSK reviewed 54 of its studies and found no increase in cardiovascular risk with abacavir. Now, in other news briefs: >Raltegravir (Isentress) has 96-week data comparing it to efavirenz and reports no new side effects or increased risk of malignancies. >Rilpivirine (TMC 278), the new once-a-day nonnucleoside reverse transcriptase inhibitor, continues to do well in Phase III trials. >Two new once-a-day NNRTIs with activity against resistant virus have completed Phase II trials with 1.8 log drops in viral load and good tolerability. They are moving toward Phase III trials. >Tenofovir now has seven-year follow-up data showing no significant impact on kidney function or bone mineral density. Limb fat increased by about 30%. >Tesamorelin (growth hormone releasing factor) at 26 weeks into its second Phase III trial showed about 10% decrease in abdominal fat without changing limb fat. It has been well-tolerated. Bowers is an HIV specialist and is board-certified in family medicine. He is in private practice in New York City.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Before AIDS, gay artist Rex drew hot men on the prowl — then he disappeared
April 11 2024 3:15 PM
Diets that mimic fasting reverse aging: study
March 07 2024 5:28 PM
PrEP without a prescription now a reality in California
February 06 2024 8:37 PM
Injectable HIV treatment, prevention: Everything you need to know
March 26 2024 3:28 PM
8 dating tips for gay men from a gay therapist
March 21 2024 2:50 PM
Happy national foreskin day!
April 04 2024 1:45 PM
The science behind U=U has been liberating people with HIV for years
June 04 2024 3:31 PM
Scarlet fever: exploring our fascination with blood
March 13 2024 1:47 PM
On Anal Sex Day, crack up with The Bottom's Digest
April 18 2024 10:22 AM
Plus: Featured Video
Latest Stories
Activist and philanthropist Bruce Bastian dies at 76
June 26 2024 1:28 PM
Yes, HIV-positive people can safely breastfeed
June 26 2024 12:59 PM
Exclusive: We kiki with Q from 'RuPaul's Drag Race'
June 24 2024 11:37 AM
Court rules to keep PrEP coverage under Obamacare
June 21 2024 5:42 PM
In honor of Juneteenth 2024, meet The Normal Anomaly
June 19 2024 1:39 PM
What is Juneteenth?
June 19 2024 11:30 AM
As Pride party season begins, the CDC urges mpox vaccinations
May 16 2024 6:52 PM
Advocacy in action with AIDSWatch
May 09 2024 12:30 PM
The Talk: Thriving with HIV
May 08 2024 10:45 AM
The Talk: What HIV isn’t
May 07 2024 10:48 AM
The Talk: Finding balance with HIV
May 06 2024 10:51 AM
Justice Dept plans to reschedule marijuana as a lower-risk drug
May 03 2024 2:40 PM
The Talk: Starting your journey with HIV
May 03 2024 2:00 PM
Why is a mother’s mental health so important? A doctor explains
May 01 2024 1:38 PM
Walmart to close all of its health care clinics
April 30 2024 12:30 PM
Vampire facial spa infected several women with HIV
April 29 2024 7:26 PM